(VTRS) Viatris - Ratings and Ratios

Viatris Inc. (NASDAQ:VTRS) is a global healthcare company with operations spanning North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. The company is organized into four key segments: Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets. Its product portfolio includes prescription brand drugs, generic drugs, complex generic drugs, and biosimilars, addressing a wide range of therapeutic areas such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy. The company also provides support services, including diagnostic clinics, educational seminars, and digital tools, to help patients manage their health more effectively.

Viatris offers its medicines in various formulations, including oral solid doses, injectables, and complex dosage forms, distributing them to retail and pharmacy establishments, wholesalers and distributors, payers, insurers, governments, and institutions. Its products are sold under well-known brands such as Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna. The company has strategic collaborations with Mapi Pharma Ltd. for long-acting glatiramer acetate depot products, Revance Therapeutics, Inc. for a biosimilar to BOTOX, and Theravance Biopharma, Inc. for the development and commercialization of revefenacin. Founded in 1961, Viatris is headquartered in Canonsburg, Pennsylvania.

3-Month Forecast: Based on the provided data, Viatris Inc. is expected to face headwinds in the near term. The stock price has been trending below its 20-day, 50-day, and 200-day simple moving averages (SMA), indicating bearish momentum. The average true range (ATR) of 0.36 suggests moderate volatility. The forward P/E of 3.51 indicates undervaluation, but the negative return on equity (RoE) of -3.40% raises concerns about profitability. Over the next three months, VTRS is likely to trade in a range of $7.20 to $8.50, with potential downside if it fails to break above the resistance level of $8.00. Upside momentum could emerge if the company demonstrates operational improvements or announces positive developments in its pipeline.